Kyorin Pharmaceutical conducted executive personnel changes on June 19, 2026. They appointed Mr. Tomohiro Okadaniya, an attorney, as a new Outside Director candidate, and announced the impending resignation of some officers.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2606\u2606\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-06.pdf","jir_short_summary":"Kyorin Pharmaceutical conducted executive personnel changes on June 19, 2026. They appointed Mr. Tomohiro Okadaniya, an attorney, as a new Outside Director candidate, and announced the impending resignation of some officers.","jir_summary":"### Overview of Executive Changes\nKyorin Pharmaceutical will implement executive personnel changes at the Ordinary General Meeting of Shareholders scheduled for June 19, 2026. They are appointing Mr. Tomohiro Okadaniya, an attorney, as an Outside Director candidate, and Mr. Norifumi Tamura, Managing Executive Officer, is scheduled to assume the role of Director. Resigning officers include Mr. Doro Oonoda and Mr. Noriyuki Kanai. This move aims to strengthen legal expertise and enhance corporate governance.\n\n### Future Corporate Activities and Strategies\nThe personnel refreshment aims to strengthen corporate governance and promote long-term business strategies. The new structure will support the company's development through legal advice and proposals, aiming to improve competitiveness. The resigning officers are expected to continue contributing as advisors, leveraging their experience.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #ExecutiveChanges, #JapanStocks","jir_key_figures":"New Outside Director Candidate: Mr. Tomohiro Okadaniya (born October 28, 1957)\nResigning officers: Mr. Doro Oonoda, Mr. Noriyuki Kanai\nScheduled change date: June 19, 2026","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011 Executive Changes and Organizational Reinforcement\uff5cMay 2026","jir_meta_description":"Kyorin Pharmaceutical is scheduled to implement executive personnel changes at the June 2026 shareholders' meeting. Details of newly appointed and departing officers are explained.","jir_og_title":"\u3010Kyorin Pharmaceutical\u3011 Executive Changes and Organizational Reinforcement\uff5cMay 2026","jir_og_description":"Detailed explanation of Kyorin Pharmaceutical's executive personnel changes. Focus on new appointments, resignations, and future strategies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-48161","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n